Expression of Bc-l2 in precancerous endometrial lesion and endometrial carcinoma

Hassan, Walaa Abd El-Mohsen; Adly, Mohamed Arafa; Ahmed, Ahmed

doi:10.21608/smj.2019.40957

Expression of Bc-l2 in precancerous endometrial lesion and endometrial carcinoma

Document Type : Original Article

Authors

¹ Department of Zoology, Faculty of Science,Sohag University.

² Department of Zoology, Faculty of Science, Sohag University.

³ Department of Pathology ,Faculty of Medicine, Sohag University.

10.21608/smj.2019.40957

Abstract

The oncogene Bcl-2 is known as a unique gene that plays an important role in the carcinogenesis pathway by blocking apoptosis. Aims: To evaluate the expression of Bcl-2 protein in normal, hyperplastic and neoplastic endometrial tissues. Materials and methods: Eighty three cases including 7 cases of normal endometrial changes, 37 cases of endometrial hyperplasia and 39 cases of endometrial adenocarcinoma were enrolled for this study. The expression of Bcl-2, ER and PR was evaluated by immunohistochemistry using streptavidin-biotin technique. Results: Non-malignant endometrial lesions tend to express significantly higher level of Bc-l2 compared to malignant endometrial lesion(p= 0.014). The expression of glandular Bc-l2 was significantly higher in hyperplasia compared to carcinoma(p=0.006).There was no significant association between Bcl-2 expression and tumors` histological type or stage orgrade. There was a correlation between Bcl-2 expression and ER or PR expression in endometrial carcinoma. Conclusions: Bcl-2 expression might represent a key in understanding the progression of endometrial neoplastic lesions.

Keywords

Main Subjects

Disease pathology

References

1. Jemal, A., R. Siegel, and E. Ward, Cancer statistics. Annals of Diagnostic Pathology, 2007. 11: p. 297–311.

2. Monika, P., et al., Estrogen Receptor βΔ6 (ERβΔ6) Isoform in Human Endometrial Hyperplasia and Adenocarcinoma. CANCER INVESTIGATION, 2004. 22: p. 211–218.

3. Sara, M.E.O., et al., Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr Med Chem, 2004. 11(8): p. 1031-1039.

4. Osford, S., et al., Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr. Med. Chem., 2004. 11(8): p. 1031-1039.

5. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, Bcl-2 family members and the mitochondria in apoptosis. Genes Dev, 1999. 13: p. 1899-1911.

6. Wang, T. and J. Phang, Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 1995. 55: p. 2487-2489.

7. Morsi, H.M., et al., The Patterns of Expression of an Apoptosis-Related CK18 Neoepitope, the Bcl-2 Proto-Oncogene, and the Ki67 Proliferation Marker in Normal, Hyperplastic, and Malignant Endometrium. Journal of Gynecological Pathology, 2000. 19: p. 118-126.

8. Ahmed, R.H., et al., TFF3 Is a Normal Breast Epithelial Protein and Is Associated with Differentiated Phenotype in Early Breast Cancer but Predisposes to Invasion and Metastasis in Advanced Disease. The American Journal of Pathology, 2012. 180(3): p. 904-916.

9. Mourizikou, A., et al., The use of an immunocytochemical double-labellingstaining can display the distribution of Bcl-2/Ki-67 cells in endome-trial adenocarcinoma as well as in normal endometrium. Clin. Lab., 2012. 58: p. 133-144.

10. Mora, L., et al., Differential diagnosis of endometrial hyperplasia and carcinoma by computerized imagecytometry of cell proliferation, apoptosis and Bcl-2 expression. Ann. Clin. Lab. Sci., 1999. 29: p. 308–315.

11. Laban, M., et al., Bcl-2 may play a role in the progression of endometrial hyperplasia and early carcinogenesis, but not linked to further tumorigenesis. Journal of Microscopy and Ultrastructure, 2015. 3: p. 19-24.

12. Erkanli, S., et al., Bcl-2 and P53 expression in endometrial carcinoma. J. Exp. Clin. Cancer Res. , 2004. 23: p. 97–103.

13. Kounelis, S., N. Kapranos, and E.e.a. Kouri, Immunohistochemical prolfile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod. Pathol. , 2000. 13: p. 379-388.

14. Appel, M., M. Edelweis, and J.e.a. Fleck, P53 and Bcl-2 as prognostic markers in endometrial carcinoma. Pathol. Oncol. Res., 2008. 14: p. 23-30.

15. Saegusa, M., et al., Bcl‐2 expression is correlated with a low apoptotic index and associated with progestrone receptor immunoreactivity in endometrial carcinomas The Journal of pathology, 1996. 180(3): p. 275-282.

16. Amalinei, C., et al., Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium Annals of Anatomy 2011. 193 p. 43–55.

17. Sivridis, E., A. Giatromaanolaki, and M.e.a. Koukourakis, Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and Bcl-2 expression. Virchows Arch., 2001. 438: p. 470-477.

18. Yamauchi, N., et al., Immunohistochemical analysis of endometrial adenocarcinoma for Bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity Int J. Gynecol Pathol., 1996. 15: p. 202–208.